Investigation of the relationship between an ATX inhibitor and the membrane lipid profiles of glioblastoma, prostate, and thyroid cancers, and its antiproliferative effect.
Project no. 32797 · Status: Kapanmış · 2025
Summary
<p>This study investigated the antiproliferative potential of inhibition of autotaxin (ATX), a lysophospholipase D that converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA) and thereby modulates LPA-dependent proliferation and migration signaling in cancer cells. A comparative design across glioblastoma, prostate and thyroid cell lines was originally planned; however, due to delayed procurement of cell lines and technical issues during culture, experiments were completed in the U87 glioblastoma cell line only. Cytotoxicity of the ATX inhibitor HA130 was assessed by the WST-1 assay at 24, 48 and 72 h, yielding IC₅₀ values of 120.10 µM, 110.8 µM (r=0.96) and 143 µM, respectively. Cell migration was monitored using a scratch-wound assay, and HA130 treatment delayed wound closure compared with untreated controls at 48 h. Membrane lipids were extracted using a modified Bligh-Dyer/Folch procedure and profiled by HPLC. HA130 exposure decreased cholesterol esters while increasing free cholesterol and phosphatidylethanolamine; phosphatidylcholine and sphingolipids were not detectable under the applied conditions. Overall, the findings suggest that ATX inhibition may influence proliferation, migration and membrane lipid organization in U87 cells, warranting further validation with additional cell models and orthogonal lipidomics approaches.</p>